Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV

Angioedema (AE) of the upper airways is a severe and potentially life-threatening condition. The incidence has been increasing in the past two decades, primarily due to increased use of medications inhibiting the degradation of vasoactive peptides. Acquired angioedema related to angiotensin-converti...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2017-01, Vol.2017, p.bcr2016217802
Main Authors: Hermanrud, Thorbjørn, Bygum, Anette, Rasmussen, Eva Rye
Format: Article
Language:English
Subjects:
Allergies
Angioedema
Angioedema - chemically induced
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Blood
Diabetes
Diagnosis, Differential
Dipeptidyl-Peptidase IV Inhibitors - adverse effects
Drug Interactions
Edema
Enzymes
Europe (West)
Humans
Hypopharynx - drug effects
Laryngeal Edema - chemically induced
Male
Middle Aged
Mouth Diseases - chemically induced
Neuropeptides
Patients
Peptides
Permeability
Pharyngeal Diseases - chemically induced
Rodents
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
White
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angioedema (AE) of the upper airways is a severe and potentially life-threatening condition. The incidence has been increasing in the past two decades, primarily due to increased use of medications inhibiting the degradation of vasoactive peptides. Acquired angioedema related to angiotensin-converting enzyme inhibitors (ACEI-AAE) is well known, but other pharmaceutical agents also affect the degradation of bradykinin and substance P. We present a middle-aged man with recurrent episodes of severe AE of the oral cavity, hypopharynx and larynx due to pharmacological inhibition of dipeptidyl peptidase IV.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2016-217802